Merck & Co., Inc. is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. The company actively monitors the business development landscape for growth opportunities that meet its strategic criteria. Merck's operations are principally managed on a products basis and include two operating segments, the pharmaceutical and animal health segments. The pharmaceutical segment includes human health pharmaceutical and vaccine products, which are sold primarily to drug wholesalers, retailers, hospitals, government agencies, and managed health care providers. The company also offers an extensive suite of digitally connected identification, traceability, and monitoring products. Merck's capital allocation priorities include investing in its pipeline and executing business development transactions, which are essential for supporting long-term growth. The company is focused on protecting the safety of its employees and ensuring that its supply of medicines and vaccines reaches its patients, contributing its scientific expertise to the development of antiviral approaches, and supporting health care providers and communities. Merck's strategic collaborations with other companies, such as Seagen and Ridgeback Biotherapeutics, aim to develop innovative therapies and vaccines, demonstrating the company's commitment to leveraging technology and partnerships to enhance its capabilities in addressing market needs. The company is also involved in various claims and legal proceedings, including product liability and environmental matters, which require careful management of its resources and capabilities. Merck's research and development expenses reflect higher costs related to business development activity and increased investment in discovery research and early drug development, which are critical for maintaining its competitive advantage. The company has made significant investments in its technology infrastructure to support its research and development efforts, including the acquisition of companies that enhance its technological capabilities and product offerings. Merck's focus on operational efficiency and strategic resource allocation is evident in its restructuring programs aimed at optimizing its manufacturing and supply network. The company continues to evaluate its global footprint and overall operating model to enhance its organizational effectiveness and agility in responding to market dynamics. Additionally, Merck's financial performance is influenced by pricing pressures and competitive actions in the pharmaceutical industry, necessitating a robust information management capability to support decision-making processes. The company's commitment to innovation and business transformation is further reflected in its ongoing efforts to develop new products and expand its market presence, ensuring that it remains a competitive force in the global health care landscape.